These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30797782)

  • 21. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
    Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
    J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W; Lu L; Li W; Jiang S
    Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
    Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
    J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
    Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K
    J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion.
    Wang S; York J; Shu W; Stoller MO; Nunberg JH; Lu M
    Biochemistry; 2002 Jun; 41(23):7283-92. PubMed ID: 12044159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
    Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
    Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
    Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
    J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. d(TGGGAG) with 5'-nucleobase-attached large hydrophobic groups as potent inhibitors for HIV-1 envelop proteins mediated cell-cell fusion.
    Chen W; Xu L; Cai L; Zheng B; Wang K; He J; Liu K
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5762-4. PubMed ID: 21873060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of HIV-1 by fusion inhibitors.
    Eggink D; Berkhout B; Sanders RW
    Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
    Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are fusion inhibitors active against all HIV variants?
    Poveda E; Rodes B; Toro C; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):347-8. PubMed ID: 15117459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.